| abstract |
REFERRING TO A COMPOUND DERIVED FROM BENZAMIDE OF FORMULA I, WHERE Z1 IS C1-C4 ALKYL, C3-C6 CYCLOALKYL, C1-C4 ALKYLTIUM, PHENYL, AMONG OTHERS; Z2 IS H, HALOGEN, C1-C4 ALKYL, AMONG OTHERS; Z3 IS H, HALOGEN, C1-C4 ALKYL, AND OTHERS; Z4 IS H, HALOGEN, ALKYLOC1-C4, AMONG OTHERS; Z5 IS H, CHLORINE, IODINE, HYDROXY, AMONG OTHERS. PREFERRED COMPOUNDS ARE: (±) -N- [2- (DIMETHYLAMINE) -2-METHYL-1-PHENYLPROPYL] -2,3-DIMETHYLBENZAMIDE, (±) -N- [2- (DIMETHYLAMINE) -2-METHYL-1 -PHENYLPROPYL] -2,6-DIMETHYLBENZAMIDE, (±) -N- [2- (DIMETHYLAMINE) -2-METHYL-1-PHENYLPROPYL] -2-METHYL-5- (TRIFLUOROMETHYL) BENZAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION AND A PREPARATION PROCEDURE. SUCH COMPOUNDS ARE INHIBITORS OF THE GLYCINE TRANSPORTER AND ARE USEFUL IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS, PARTICULARLY, PSYCHOSIS, DEMENTIA OR ATTENTION DEFICIT DISORDER |